KRAS and plasma cell leukemia: N-RAS or K-RAS genetic or epigenetic aberrant activations are associated with poor prognosis in plasma cell leukemia (PCL), an aggressive HM originating from secondary leukemic transformation of MM (Aldoss et al., 2019), and in ALL (Mullighan et al., 2011).